Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
3 clinical trials · Condition
◉ Watch Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study (NCT06805812) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2023-05-01 |
| Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (NCT05286437) | National Cancer Centre, Singapore | 2023-02-15 |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (NCT02333370) | Novartis Pharmaceuticals | 2015-02-04 |
Track Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.